Q4 2025 Regeneron Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Regeneron Pharmaceuticals Inc (REGN) reported a 3% year-over-year increase in total revenue for the fourth quarter of 2025, driven by strong sales growth in key products like Dupixent, Libtayo, and EYLEA HD.
- Dupixent achieved global net sales of $4.9 billion in the fourth quarter and $17.8 billion for the full year 2025, marking a 32% increase year-over-year, with significant growth potential in underpenetrated indications.
- Libtayo's net product sales reached $425 million in the fourth quarter, with strong market leadership in advanced non-melanoma skin cancers and growing share in non-small cell lung cancer.
- EYLEA HD's net product sales in the United States increased by 66% in the fourth quarter, with recent FDA approvals enhancing its clinical profile and commercial potential.
- Regeneron Pharmaceuticals Inc (REGN) anticipates at least four FDA approvals in the next 12 months, including three for new molecular entities, positioning the company for future growth.
- EYLEA 2 milligrams faces competitive pressure, with anticipated intensification in the second half of 2026 due to the launch of multiple biosimilar products in the United States.
- Patient co-pay affordability issues continue to dampen growth in the branded anti-VEGF category, impacting EYLEA HD's commercial potential.
- Regeneron Pharmaceuticals Inc (REGN) is engaged in ongoing negotiations with the United States government regarding efforts to reduce drug costs, which could impact future pricing and profitability.
- The company's R&D expenses are expected to increase significantly in 2026, driven by costs to support an expanding late-stage pipeline, potentially impacting short-term profitability.
- Regeneron Pharmaceuticals Inc (REGN) faces challenges in maintaining its leadership in the competitive ophthalmology and immunology markets, with numerous companies attempting to develop similar products.
Welcome to the Regeneron Pharmaceuticals fourth-quarter 2025 earnings conference call. My name is Shannon, and I will be your operator for today's call. (Operator Instructions) Please note that this conference call is being recorded.
I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may begin.
Thank you, Shannon. Good morning, good afternoon, and good evening to everyone listening around the world. Thank you for your interest in Regeneron and welcome to our fourth-quarter 2025 earnings conference call. An archive and transcript of this call will be available on the Regeneron Investor Relations website shortly after our call concludes.
Joining me on today's call are Dr. Leonard Schleifer, Board, Co-Chair, Co-Founder, President, and Chief Executive Officer; Dr. George Yancopoulos, Board, Co-Chair, Co-Founder, President, and Chief Scientific Officer; Marion McCourt, Executive Vice President of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
